Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework

Affiliations

¹ Evidence Synthesis and Modelling for Health Improvement, Institute of Health Research, University of Exeter Medical School, Exeter EX1 2LU, UK; and the Centre for Research on Health and Social Care Management, Bocconi University, 20100 Milan, Italy.
² International Drug Development Institute, 1340 Louvain-la-Neuve, Belgium.
³ Centre for Health Economics, University of York, York YO10 5DD, UK.
⁴ European Medicine Agency, London E14 5EU, UK; and the University of Rome Tor Vergata, 00173 Rome, Italy.
⁵ Dendrix Research, 04534-000 Sao Paulo, Brazil.
⁶ Evidence Synthesis and Modelling for Health Improvement, Institute of Health Research, University of Exeter Medical School, Exeter EX1 2LU, UK.

Free article

Oriana Ciani et al. Nat Rev Drug Discov. 2016 Jul.

Free article

. 2016 Jul;15(7):516.

doi: 10.1038/nrd.2016.81. Epub 2016 Jun 3.

¹ Evidence Synthesis and Modelling for Health Improvement, Institute of Health Research, University of Exeter Medical School, Exeter EX1 2LU, UK; and the Centre for Research on Health and Social Care Management, Bocconi University, 20100 Milan, Italy.
² International Drug Development Institute, 1340 Louvain-la-Neuve, Belgium.
³ Centre for Health Economics, University of York, York YO10 5DD, UK.
⁴ European Medicine Agency, London E14 5EU, UK; and the University of Rome Tor Vergata, 00173 Rome, Italy.
⁵ Dendrix Research, 04534-000 Sao Paulo, Brazil.
⁶ Evidence Synthesis and Modelling for Health Improvement, Institute of Health Research, University of Exeter Medical School, Exeter EX1 2LU, UK.

No abstract available

References